Needham has initiated coverage on NewAmsterdam Pharma (NAMS) with a Buy rating and a $36 price target, citing the potential of their cholesterol-lowering drug, obicetrapib. The drug demonstrated significant LDL-C reduction in a Phase 3 trial and could generate blockbuster sales by targeting a large patient population.